| Trial ID: | L6243 |
| Source ID: | NCT06549556
|
| Associated Drug: |
Colostrum Capsule 500 Mg (Colostrum® 500 Mg Veg Capsules, Nowfoods®, Illinois, Usa)
|
| Title: |
The Value of Using Colostrum Supplements on the Physical Performance and Cognitive Function in Healthy Subjects and Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA)|OTHER: Placebo
|
| Outcome Measures: |
Primary: Serum IL-1 Level, Measured in Pg/mL, at Baseline, and After 60 days of treatment.|Serum IL-15 Level, Measured in Pg/mL, at Baseline, and After 60 days of treatment.|Fasting Blood Sugar (FBS), Measured in mg/dL, at Baseline, and After 60 days of treatment.|Hemoglobin A1C (HbA1C), Measured in percent from total Hemoglobin, at Baseline, and After 60 days of treatment.|Body Mass Index (BMI), Measured in Kg/m², at baseline, and after 60 days of treatment. | Secondary: Serum C-reactive protein (CRP), Measured in mg/dL, At baseline, and after 60 days of treatment|Rate Pressure Product, Measured in an equation combining Heart rate in (BPM) and blood pressure in (mmHg), at Baseline, and after 60 days of treatment.
|
| Sponsor/Collaborators: |
Sponsor: Al-Rasheed University College | Collaborators: Al-Farabi Kazakh National University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
100
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT
|
| Start Date: |
2024-08-20
|
| Completion Date: |
2024-12-10
|
| Results First Posted: |
|
| Last Update Posted: |
2024-12-13
|
| Locations: |
Al-Zahraa Teaching Hospital, Wasit, 52001, Iraq
|
| URL: |
https://clinicaltrials.gov/show/NCT06549556
|
